Red Light Holland (TRIP) AI Stock Analysis

• Market Cap: C$10.64M
• Dividend Yield: N/A
• Average Volume (3M): 212.42K
• Price to Earnings (P/E): ―
• Beta (1Y): 0.64
• Revenue Growth: -28.00%
• EPS Growth: 38.46%
• Country: CA
• Employees: N/A
• Sector: Healthcare
• Sector Strength: 45
• Industry: Drug Manufacturers - Specialty & Generic
• EPS (TTM): >-0.01
• Shares Outstanding: 425,710,720
• 10 Day Avg. Volume: 258,444
• 30 Day Avg. Volume: 212,422
• PEG Ratio: -0.09
• Price to Book (P/B): 1.18
• Price to Sales (P/S): 4.99
• P/FCF Ratio: -6.05
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 48 Neutral
• Price Target: C$0.03 ▲(25.00% Upside)
• Action: Reiterated Date: 03/14/26
• Date: Action: Reiterated 03/14/26

The score is held back mainly by weak financial performance—ongoing losses and negative operating/free cash flow—despite strong revenue growth and a relatively solid, low-debt balance sheet. Technicals are supportive with price above major moving averages and a positive MACD, but overbought signals (RSI ~69, Stoch 100) raise near-term pullback risk. Valuation is constrained by negative earnings and no dividend yield data.

Positive Factors

Niche Licensed Market Position

Having licensed, legal operations and branded product distribution in the Netherlands gives the company a durable, regulated commercial foothold in the nascent psychedelics consumer market. This supports repeatable sales channels, brand-building and scale where activity is permitted.

Low Leverage Balance Sheet

A low-debt, sizable equity base provides financial flexibility to fund growth, absorb regulatory or demand volatility, and pursue product development or market expansion without immediate refinancing. It offers downside protection while the business seeks profitability.

Revenue Scaling with Positive Gross Margins

Material top-line scaling combined with positive gross margins indicates underlying product demand and viable unit economics for core truffle products. If fixed operating costs are controlled, these fundamentals support potential margin expansion as revenue grows further.

Negative Factors

Persistent Negative Profitability

Sustained net losses and materially negative operating margins undermine return on invested capital and can erode equity over time. Without a clear path to sustainable profitability, the company may need repeated external capital or structural cost reductions to preserve long-term viability.

Ongoing Cash Burn

Negative operating and free cash flow limit financial flexibility and increase reliance on external financing or equity issuance. Even with reported FCF improvement vs prior period, persistent cash burn risks dilution, constrains investment in commercialization, and heightens funding risk.

Single-Jurisdiction Concentration Risk

Heavy dependence on the Netherlands legal market concentrates revenue and regulatory exposure. Adverse legal, tax, or market developments in that jurisdiction could materially impair sales growth prospects and delay broader international expansion opportunities.

Red Light Holland Business Overview & Revenue Model

Company Description

Red Light Holland Corp. (TRIP) is a Canadian company focused on the production and distribution of psilocybin truffles, marketed primarily for recreational and therapeutic use. Operating in the emerging psychedelics sector, Red Light Holland aims to provide high-quality, safe, and consistent products to consumers, leveraging a strong brand presence and innovative cultivation methods. The company is also engaged in education and advocacy efforts surrounding responsible use and the potential benefits of psychedelics.

How the Company Makes Money

Red Light Holland primarily makes money by selling legal psilocybin truffle products and related branded offerings in jurisdictions where they are permitted, with its core commercial activity centered on the Netherlands’ legal market for psilocybin-containing truffles. Revenue is generated through (1) direct-to-consumer and/or retail distribution sales of packaged truffles and microdosing-oriented products sold under company brands, and (2) wholesale or business-to-business supply where applicable, by producing truffles and supplying finished or bulk products into legal sales channels. The company’s earnings are influenced by its ability to cultivate and manufacture at scale, maintain compliant distribution in regulated markets, and build consumer demand through brand, product formats (e.g., microdosing), and marketing in permitted regions. Specific breakdowns of revenue by channel, named major customers, or material partnership-driven revenue contributions are null.

Red Light Holland Financial Statement Overview

Summary

Strong revenue scaling and a low-leverage balance sheet are positives, but they are outweighed by deeply negative net income, materially negative operating/net margins, and continued negative operating and free cash flow (cash burn), despite some improvement in free cash flow versus the prior period.

Income Statement

Revenue has scaled up materially over time, with TTM (Trailing-Twelve-Months) revenue up sharply versus the prior annual period, showing demand traction. However, profitability remains weak: TTM (Trailing-Twelve-Months) net income is deeply negative and margins are still materially below zero (operating and net), indicating the business has not yet converted growth into sustainable earnings. Gross margin is positive and decent in TTM (Trailing-Twelve-Months), but operating costs continue to overwhelm gross profit.

Balance Sheet

The balance sheet is a relative strength, with low leverage: TTM (Trailing-Twelve-Months) debt is small versus equity and the debt-to-equity ratio is very low. Equity remains sizable, providing financial flexibility and some downside protection. The key weakness is value creation: return on equity is strongly negative in TTM (Trailing-Twelve-Months), reflecting ongoing losses that can erode the equity base over time if not corrected.

Cash Flow

Cash generation remains pressured, with TTM (Trailing-Twelve-Months) operating cash flow and free cash flow both negative, implying the company is still cash-burning. A positive sign is that free cash flow has improved versus the prior annual period (strong positive growth rate), suggesting the burn rate may be moderating. Still, cash flow has not yet turned self-funding, and negative operating cash flow reduces flexibility without external financing.

Breakdown	TTM	Jun 2024	Jun 2023	Jun 2022	Jun 2021	Mar 2020
Income Statement
Total Revenue	4.17M	4.94M	4.75M	3.95M	2.33M	0.00
Gross Profit	1.27M	1.91M	2.02M	1.71M	617.68K	0.00
EBITDA	-4.36M	-3.35M	-6.58M	-4.32M	-8.55M	0.00
Net Income	-4.77M	-4.04M	-7.63M	-5.40M	-14.37M	-325.17K
Balance Sheet
Total Assets	18.20M	21.22M	24.08M	30.14M	32.94M	3.97M
Cash, Cash Equivalents and Short-Term Investments	9.88M	12.27M	14.17M	18.53M	26.62M	1.96M
Total Debt	501.66K	2.18M	1.72M	1.77M	1.50M	86.77K
Total Liabilities	3.58M	3.87M	3.82M	3.80M	3.78M	5.11M
Stockholders Equity	14.69M	17.35M	20.07M	26.06M	28.48M	-1.14M
Cash Flow
Free Cash Flow	-2.69M	-2.01M	-3.92M	-6.45M	-5.28M	-238.35K
Operating Cash Flow	-2.51M	-1.48M	-3.23M	-4.39M	-4.88M	-238.35K
Investing Cash Flow	-1.16M	-525.40K	-650.43K	-3.17M	-582.74K	-1.80M
Financing Cash Flow	-490.68K	445.17K	-206.95K	-114.16K	451.76K	4.01M

Red Light Holland Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 0.02
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Negative

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TSE:TRIP, the sentiment is Positive. The current price of 0.02 is above the 20-day moving average (MA) of 0.02, above the 50-day MA of 0.02, and below the 200-day MA of 0.03, indicating a neutral trend. The MACD of <0.01 indicates Negative momentum. The RSI at 69.11 is Neutral, neither overbought nor oversold. The STOCH value of 100.00 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for TSE:TRIP.

Red Light Holland Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
MUSH	54 Neutral	C$7.75M	-7.07	-99.55%	―	-26.71%	-988.89%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
CWEB	51 Neutral	C$124.35M	-1.15	-119.94%	―	-4.23%	37.33%
CURA	50 Neutral	C$2.44B	―	-28.58%	―	-3.38%	-31.35%
TRIP	48 Neutral	C$10.64M	-1.51	-23.76%	―	-28.00%	38.46%
RVV	46 Neutral	C$29.30M	-4.56	899.59%	―	―	-80.42%
PLTH	42 Neutral	C$68.33M	-0.45	-90.71%	―	2.19%	-91.41%

Red Light Holland Corporate Events

Red Light Holland Narrows Focus as Q3 Revenue Rises but Profits Tighten

Red Light Holland reported third-quarter 2026 results showing an 8.3% year-over-year revenue increase to $1.27 million, but a 13.7% decline in gross profit and a slightly higher adjusted EBITDA loss of $0.71 million, while cash fell to $9.24 million amid investment in Bitcoin ETFs and high-interest savings vehicles. Management highlighted normalized sales versus the prior quarter, lower G&A expenses, the shutdown of shiitake mushroom production at AEM to focus on near-profitable operations, and progress in psilocybin R&D through its DEA-registered partner Irvine Labs, underscoring a strategic pivot toward an R&D-driven model and active evaluation of M&A from a relatively strong balance-sheet position.

The most recent analyst rating on (TSE:TRIP) stock is a Hold with a C$0.02 price target. To see the full list of analyst forecasts on Red Light Holland stock, see the TSE:TRIP Stock Forecast page.